Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A phase 2 trial of Selinexor in diffuse large b-cell lymphoma, run by Karyopharm Therapeutics Inc, active and no longer recruiting.
Overview
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) is a phase 2 interventional study registered as NCT02227251 by Karyopharm Therapeutics Inc, with 244 participants planned, started 2014-11 and due to reach its primary completion in 2026-12. Interventions recorded: Selinexor, Selinexor, Selinexor. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialXPORT-EC-042 / ENGOT-EN20 / GOG-3083
Shares Karyopharm Therapeutics, Selinexor.
- TrialStudy of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Shares Karyopharm Therapeutics, Selinexor.
- TrialA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly
Shares Karyopharm Therapeutics, Selinexor, Diffuse large B-cell lymphoma.
- TrialA Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac
Shares Karyopharm Therapeutics, Selinexor.
- TrialSelinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Karyopharm Therapeutics, Selinexor.
- CompanyAntengene
Shares Selinexor, Diffuse large B-cell lymphoma.
- TargetExportin-1 (XPO1)
Shares Selinexor, Diffuse large B-cell lymphoma.